Timing of Levetiracetam (Keppra) Trough Level for BID Dosing
Draw the levetiracetam trough level immediately before the next scheduled dose (predose), ideally in the morning before the first daily dose when the patient is at steady state.
Key Timing Principles
When to Draw the Level
- Trough timing: Obtain the blood sample just before the next scheduled dose 1
- Steady state: Wait until steady state is achieved, which occurs after 2 days of twice-daily dosing 1
- Practical approach: The morning predose level (before the first BID dose) is most convenient and standardized for monitoring
Pharmacokinetic Rationale
Levetiracetam has a plasma half-life of 6-8 hours in adults 1. With BID dosing, steady state is reached quickly (within 48 hours), making trough levels reliable after just 2 days of therapy 1. The trough represents the lowest concentration and is the standard monitoring point for assessing whether therapeutic levels are maintained throughout the dosing interval.
Clinical Context for Monitoring
When TDM is Actually Indicated
While routine therapeutic drug monitoring (TDM) of levetiracetam is generally unnecessary due to its predictable pharmacokinetics and broad therapeutic window 2, monitoring may be beneficial in:
- Critically ill patients (augmented clearance may require higher doses) 3, 4
- Pediatric patients (30-40% increased clearance vs adults) 2
- Elderly patients (38% decreased clearance) 2
- Pregnant patients (declining levels as pregnancy progresses) 2
- Renal impairment (66% of drug renally excreted unchanged) 1
- Patients on CVVH or dialysis 5
Target Therapeutic Range
The commonly cited reference range is 12-46 μg/mL (or 6-20 mg/L in some sources) 4, though there is no established correlation between serum levels and efficacy or toxicity 2. Individual therapeutic ranges may be more clinically relevant than population-based targets.
Important Caveats
No need for therapeutic drug monitoring in most patients: Unlike phenytoin or valproate, levetiracetam has linear pharmacokinetics, minimal protein binding (<10%), and no significant drug-drug interactions 1. Routine monitoring is not recommended for the general epilepsy population 2.
Peak levels are not routinely obtained: Unlike aminoglycosides, peak levetiracetam levels are not part of standard monitoring. If needed for research or special circumstances, peak occurs approximately 1 hour after oral administration in fasted patients 1.
Dosing adjustments should be based on clinical response first: Seizure control and adverse effects (CNS depression, irritability) are more important than achieving a specific number 6.